L575-0210 Screening compound: 4-[1-methyl-3-(1-pyrrolidinylcarbonyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-N-(2-morpholinoethyl)-4-oxobutanamide

L575-0210 Screening compound: 4-[1-methyl-3-(1-pyrrolidinylcarbonyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-N-(2-morpholinoethyl)-4-oxobutanamide
L575-0210 Screening compound: 4-[1-methyl-3-(1-pyrrolidinylcarbonyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-N-(2-morpholinoethyl)-4-oxobutanamide alternative view

Chemical Structure Depiction of ChemDiv screening compound L575-0210
4-[1-methyl-3-(1-pyrrolidinylcarbonyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-N-(2-morpholinoethyl)-4-oxobutanamide

Available from 1 mg

Formats:

  • Glass Vials (4ml Glass Vials VWR #97047-678)
  • 96-tube racks (Matrix #4247 96-well 1.4ml sealed with capmats, empty cols 1 & 12, 100uL of 10mM)

Shiptime: 1 week worldwide delivery in most cases

Compound Identifiers

ChemDiv Compound ID

L575-0210

Molecular Formula

C22H34N6O4 (C22 H34 N6 O4)

Compound Name

4-[1-methyl-3-(1-pyrrolidinylcarbonyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl]-N-(2-morpholinoethyl)-4-oxobutanamide

IUPAC name

4-[1-methyl-3-(pyrrolidine-1-carbonyl)-1H4H5H6H7H-pyrazolo[43-c]pyridin-5-yl]-N-[2-(morpholin-4-yl)ethyl]-4-oxobutanamide

SMILES

Cn1nc(C(N2CCCC2)=O)c(C2)c1CCN2C(CCC(NCCN1CCOCC1)=O)=O

InChI

InChI=1S/C22H34N6O4/c1-25-18-6-10-28(16-17(18)21(24-25)22(31)27-8-2-3-9-27)20(30)5-4-19(29)23-7-11-26-12-14-32-15-13-26/h2-16H2,1H3,(H,23,29)

InChI Key

FJHVWPBEFRZEGO-UHFFFAOYSA-N

MDL Number (MFCD)

MFCD27642029

Chemical and Physical Properties

Saltdata

n/a

Molecular Weight

446.55

Hydrogen Bond Acceptors Count

9.00

Hydrogen Bond Donors Count

1.00

Rotatable Bond Count

10.00

Number of Nitrogen and Oxygen Atoms

10

Partition Coefficient, logP

-1.711

Distribution Coefficient, logD

-1.787

Water Solubility, LogSw

-0.08

Polar Surface Area

84.257

Acid Dissociation Constant (pKa)

13.73

Base Dissociation Constant (pKb)

6.68

Number of Chiral Centers

0.00

Percent sp3 carbon bonding

72.73

L575-0210 in Drug Discovery

Included in Screening Libraries

Anticancer Library (62698 compounds)

300k Representative Compounds Library (Bemis-Murcko Clustering Algorithm) (286253 compounds)

Cysteine Proteases Inhibitors Library (7839 compounds)

Hsp90-Targeted Library (11355 compounds)

Included in 1.7M Stock Database

Therapeutical areas:
  • Cancer
  • Infections
  • Cancer
  • Musculoskeletal
  • Digestive system
  • Nervous system
  • Cardiovascular
  • Skin
  • Metabolic
  • Endocrine
  • Immune system
  • Cancer
  • Digestive system
  • Respiratory tract
  • Male
  • Female
  • Hemic and lymphatic
  • Immune system
Targets:
  • Proteases

References: we are preparing a list of scientific research reports with L575-0210 chemical compound. It will be published here after verification.

Frequently Asked Questions

How to purchase chemical compound L575-0210?
Check Price and Availability of L575-0210, then you can add required amount to the Shopping Cart. In the Shopping Cart you can again refine your selection. Once you are sure that it’s exactly what you want you can move forward with the Checkout (to pay online by credit card, or via PayPal), or Request a Quote.
What is the minimum amount of L575-0210 you sell to drug discovery company or institution?
Available from 1 mg in Glass Vials or 96-tube racks.
Delivery options for L575-0210
ChemDiv sends parcels with Express services (UPS, WC).
  • 1–2 days for small orders
  • 2–4 weeks for large selections
Delivery formats for L575-0210
  • 0.5–50 mg of dry powder sample in single glass vials, custom vials
  • DMSO solutions frozen 10μl–250μl@10mM (96 and 384 format)

Custom synthesis of L575-0210 available by request